Levi & Korsinsky announces it has commenced an investigation of Prothena Corporation (“Prothena” or “the Company”) (NASDAQGS: PRTA) concerning possible violations of federal securities laws. On October 15, 2015, Prothena announced its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, Prothena announced it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. Following this news, shares of Prothena fell from a close of $36.84 on April 20, 2018, to a close of $11.50 per share on April 23, 2018. To obtain additional information on the Prothena class action investigation (PRTA class action investigation), go to: http://www.zlk.com/pslra-d/prothena-corporation or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
For more information on the Prothena investigation (PRTA investigation), contact Levi & Korsinsky. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.